Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 276 clinical trials
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

/or right sided tumors will be randomised between doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab (schedule 1), and triple chemotherapy (FOLFOXIRI) plus bevacizumab (schedule 2). Patients

cancer
bevacizumab
systemic therapy
BRAF
metastasis
  • 247 views
  • 11 Nov, 2021
  • 67 locations
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma Ependymoma and ATRT

endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly intravenous bevacizumab in combination with five oral drugs (thalidomide, celecoxib, fenofibrate

bevacizumab
karnofsky performance status
combinations
ependymoma
medulloblastoma
  • 57 views
  • 17 Sep, 2021
  • 27 locations
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

includes bevacizumab in the combination. The study is proceeding as expected after >100 patients enrolled and under independent Data Monitoring Committee (IDMC) supervision. Platinum-containing

  • 7 views
  • 20 Aug, 2021
  • 100 locations
A Trial to Compare the Efficacy Safety Pharmacokinetics and Immunogenecity of HD204 to Avastin in Advanced Non-squamous Non-small Cell Lung Cancer Patients

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin in terms of efficacy, safety, pharmacokinetics and immunogenecity.

cancer
carboplatin
bevacizumab
carboplatin/paclitaxel
lung cancer
  • 218 views
  • 18 Sep, 2021
  • 23 locations
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with p53-mutated ED SCLC undergoing 2nd-line treatment with topotecan. (Part 1 has completed enrollment). …

carboplatin
kidney function test
platinum-based chemotherapy
topotecan
cancer chemotherapy
  • 2 views
  • 11 Jul, 2021
  • 6 locations
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma

The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.

  • 0 views
  • 17 Dec, 2021
  • 14 locations
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued …

undifferentiated carcinoma
tumor cells
carcinoma
absolute neutrophil count
metastasis
  • 1853 views
  • 18 Jan, 2022
  • 212 locations
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) …

bone scan
cancer
stereotactic body radiation therapy
metastasis
positron emission tomography
  • 31 views
  • 20 Oct, 2021
  • 14 locations
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous

chemoembolization
TACE
  • 6 views
  • 26 Jan, 2021
  • 7 locations
Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma Phase III

The aim of this Phase III study is to evaluate the superiority of dose-dense temozolomide (ddTMZ) followed by bevacizumab at ddTMZ failure for glioblastoma at first recurrence or progression

carmustine
optic nerve
temozolomide
astrocytoma
MRI
  • 541 views
  • 10 Sep, 2021
  • 37 locations